We have validated the efficacy of delivering and generating EphA2‐CAR mRNA with m1ψ modification to NK92 and primary human NK cells, demonstrating enhanced target specificity against the EphA2 antigen in sarcoma cells. This evidence concerns the gene EPHA2 and sarcoma.